What Happens When Tagrisso Stops Working?
Written by Dr. Zack Ferris in TheSkyMeds Editorial Standards
Medically reviewed by Jonathan Reed, Medical Content Reviewer Oct 3 2026
When Tagrisso stops working, it usually means EGFR-mutated non-small cell lung cancer (NSCLC) has started growing again despite treatment with osimertinib, the generic name for Tagrisso. This is called disease progression or acquired resistance, and it does not automatically mean that all treatment options have been exhausted. The next step depends on where the cancer is growing, whether progression is limited or widespread, which treatments you have already received, and what new molecular changes are present in the tumor. Doctors may use scans, blood-based circulating tumor DNA testing, and sometimes another tissue biopsy to understand what has changed. Treatment after progression may include local radiation for selected areas, chemotherapy, newer EGFR/MET-directed treatments, antibody-drug conjugates, or clinical trials. This guide explains why Tagrisso resistance occurs, what testing may be needed, and which treatment approaches may be considered next.
What Does It Mean When Tagrisso Stops Working?
When Tagrisso stops working, cancer cells have usually developed ways to survive despite continued EGFR inhibition. Sometimes only one or a few cancer spots begin growing, while the rest of the disease remains controlled; in other cases, progression occurs in several organs or throughout the body.
Tagrisso, or osimertinib, is a third-generation EGFR tyrosine kinase inhibitor used in several settings for EGFR-mutated NSCLC, including advanced disease, after surgery in selected patients, and after chemoradiation for certain unresectable stage III cancers. The meaning of progression therefore depends partly on why you were taking Tagrisso in the first place.
This article focuses mainly on locally advanced or metastatic EGFR-mutated NSCLC, where Tagrisso is being used to control active cancer.
The NCI non-small cell lung cancer treatment guidance describes osimertinib as an established EGFR-directed treatment and summarizes current evidence for treatment strategies after progression in advanced EGFR-mutated disease.
Different Ways Cancer Can Progress During Tagrisso Treatment
Progression pattern | What it means | What doctors may consider |
One or a few growing spots | Often called oligoprogression; most cancer may still be controlled | Local treatment such as stereotactic radiation or surgery in selected cases, sometimes while continuing osimertinib |
Progression mainly in the brain | Cancer is growing in the central nervous system | Brain MRI, local radiation or other CNS-directed treatment, and review of systemic therapy |
Multiple new or growing lesions | Suggests broader resistance to current treatment | Molecular reassessment and a change in systemic therapy are often considered |
New symptoms without clear scan progression | Symptoms may have another cause, including infection, blood clot, treatment toxicity, or another medical problem | Prompt clinical assessment rather than assuming Tagrisso resistance |
Recurrence after adjuvant Tagrisso | Cancer has returned after treatment intended to reduce recurrence risk | Restaging and a new treatment plan based on the sites of recurrence and tumor biology |
The important point is that “progression” is not always all-or-nothing. A treatment may still suppress much of the cancer even when a resistant group of cells begins growing elsewhere.
Why Does Resistance to Tagrisso Develop?
Cancer cells can evolve under the pressure of treatment. Osimertinib continues blocking EGFR-sensitive cells, but over time some tumor cells may acquire or select genetic and biological changes that allow them to survive without responding adequately to the drug.
Resistance mechanisms fall into several broad groups. Some directly alter EGFR itself, while others allow the cancer to bypass EGFR and activate a different growth pathway. Recent research describes mechanisms including EGFR C797S mutations, MET amplification, HER2 alterations, changes in downstream signaling pathways, oncogenic gene fusions, and transformation of the tumor into a different histological type such as small-cell lung cancer.
The recent research on osimertinib resistance mechanisms emphasizes that resistance can be highly heterogeneous. More than one resistance mechanism may exist in the same person or even in different tumor sites at the same time.
EGFR-dependent resistance
Some tumors develop an additional alteration in EGFR. One recognized example is C797S, which changes the part of the EGFR protein where osimertinib binds and can therefore reduce the drug's effectiveness.
Finding an EGFR resistance mutation does not automatically identify a routinely approved next drug. Several next-generation EGFR inhibitors remain under clinical investigation, so treatment depends on the exact mutation and available clinical trials.
Bypass-pathway resistance
The cancer may activate a different signaling route rather than changing EGFR itself. MET amplification is one of the best-recognized examples after osimertinib and has become an important target of research and combination-treatment strategies.
HER2 alterations and changes involving pathways such as RAS-MAPK or PI3K can also contribute to resistance. These findings are one reason comprehensive molecular testing can be useful after progression.
Histological transformation
Occasionally, EGFR-mutated adenocarcinoma can transform into small-cell lung cancer or another tumor phenotype. This matters because treatment may then need to follow a very different approach.
A blood-based genetic test cannot show what cancer cells look like under a microscope. Tissue biopsy can therefore be particularly important when doctors suspect transformation.
Tagrisso resistance is not one disease with one next treatment. Understanding whether progression is limited or widespread—and whether the tumor has developed an EGFR mutation, MET-driven resistance, another molecular alteration, or histological transformation—can directly influence what doctors consider next.
What Tests Are Done After Tagrisso Progression?
Doctors usually begin by confirming where and how much the cancer has progressed. This commonly involves CT imaging and may include brain MRI, PET imaging, or other tests depending on symptoms and previous cancer sites.
Molecular reassessment can then help search for resistance mechanisms. This may involve circulating tumor DNA, often called ctDNA or liquid biopsy, tissue biopsy, or both.
A 2025 prospective study evaluating patients progressing on first-line osimertinib found that tissue and plasma testing did not always identify the same resistance mechanisms. Combining both approaches detected more alterations than relying on either method alone.
What can a liquid biopsy show?
A liquid biopsy examines tumor-derived DNA fragments circulating in the blood. It can identify certain mutations and other molecular changes without requiring an invasive tumor biopsy.
It is convenient and can provide information from cancer cells throughout the body. However, not every tumor sheds enough DNA into the bloodstream, so a negative liquid biopsy does not necessarily mean that no resistance mechanism exists.
Why might another tissue biopsy be needed?
Tissue can provide both molecular information and the actual appearance of the cancer cells. This can identify transformations—such as a change from adenocarcinoma to small-cell lung cancer—that blood testing alone cannot reliably establish.
Recent real-world data also found higher detection of resistance mechanisms with tissue rebiopsy than with liquid biopsy alone, although feasibility depends on where the progressing tumor is located.
Does every resistance mechanism have an approved treatment?
No. Molecular testing can identify potentially important changes, but not every finding has an approved targeted therapy in this setting.
Some results may instead help determine eligibility for a clinical trial. Interpretation by a thoracic oncology team or molecular tumor board can be valuable when the molecular findings are complex.
Can Tagrisso Sometimes Be Continued After Progression?
Yes, in carefully selected cases. If only a small number of cancer sites are progressing while most disease remains controlled, doctors may consider treating those resistant areas locally and continuing osimertinib because the drug may still be controlling the remaining cancer.
This approach is known as treatment beyond progression and is most often discussed for oligoprogressive disease. Local therapy can include stereotactic body radiation therapy, stereotactic radiosurgery for selected brain lesions, or occasionally surgery.
A recent phase II study evaluated local ablative treatment followed by osimertinib rechallenge in oligoprogressive EGFR-mutated NSCLC. The overall benefit was limited and the trial did not meet its primary historical comparison goal, although selected patients appeared to benefit, reinforcing that this approach should be individualized rather than applied routinely.
Other recent studies and reviews continue to support evaluating local therapy in carefully selected oligoprogressive patients while emphasizing that stronger prospective evidence is still needed.
Continuing Tagrisso is much less straightforward when progression is widespread. In that situation, switching systemic therapy is more commonly considered.
Do not continue, stop, or restart Tagrisso independently after a scan shows progression. The decision depends on the progression pattern, previous treatment, symptoms, and planned next therapy.
What Treatments May Come After Tagrisso?
Several treatment options now exist after osimertinib progression, but the appropriate sequence depends on the original EGFR mutation, previous chemotherapy exposure, progression pattern, molecular results, overall health, and which treatments are approved and available in your country.
Treatment Approaches That May Be Considered After Tagrisso Progression
Clinical situation | Possible approach | Important context |
Limited or oligoprogressive disease | Local radiation or occasionally surgery, with possible continuation of osimertinib | Appropriate only for selected patients |
Widespread progression after osimertinib | Platinum-based chemotherapy, commonly using pemetrexed for nonsquamous NSCLC | Choice depends on prior chemotherapy and overall health |
EGFR exon 19 deletion or L858R disease progressing after an EGFR TKI | Amivantamab plus carboplatin and pemetrexed | FDA-approved in the U.S.; availability and indications differ by country |
Progression after EGFR-directed therapy and platinum chemotherapy | Datopotamab deruxtecan may be an option | U.S. accelerated approval applies to previously treated EGFR-mutated locally advanced or metastatic NSCLC |
Actionable resistance mechanism found | Biomarker-directed therapy or a clinical trial may be considered | Not every molecular alteration has an approved treatment |
No clear resistance mechanism | Systemic therapy is selected according to previous treatment and overall clinical situation | Clinical-trial participation may also be considered |
Amivantamab plus chemotherapy
In September 2024, the FDA approved amivantamab-vmjw with carboplatin and pemetrexed for adults with locally advanced or metastatic NSCLC containing EGFR exon 19 deletions or exon 21 L858R mutations whose disease progressed on or after an EGFR tyrosine kinase inhibitor.
The FDA amivantamab approval after EGFR-TKI progression was based on the MARIPOSA-2 study. In that trial, patients had progressed on or after osimertinib, and amivantamab plus carboplatin/pemetrexed improved progression-free survival compared with chemotherapy alone.
Amivantamab is an EGFR-MET bispecific antibody. Treatment has its own potential adverse effects, including infusion or administration reactions, skin and nail problems, and other toxicities, so it requires oncology supervision.
A subcutaneous formulation of amivantamab with hyaluronidase was also approved in the U.S. for the indications covered by intravenous amivantamab, adding another administration option where available.
Platinum-based chemotherapy
Platinum chemotherapy remains an important treatment component after EGFR-targeted therapy.
Carboplatin or cisplatin is commonly paired with pemetrexed for nonsquamous NSCLC, although the exact regimen depends on previous therapy and medical fitness.
For someone who already received chemotherapy with first-line osimertinib, choosing the next treatment becomes more complex because evidence from traditional post-osimertinib studies may not apply in exactly the same way.
Datopotamab deruxtecan after EGFR therapy and chemotherapy
In June 2025, the FDA granted accelerated approval to datopotamab deruxtecan-dlnk for adults with locally advanced or metastatic EGFR-mutated NSCLC who had already received both EGFR-directed therapy and platinum-based chemotherapy.
The FDA approval of datopotamab deruxtecan for previously treated EGFR-mutated NSCLC reported a confirmed response rate of 45% in the pooled population used for the approval, with a median response duration of 6.5 months. Because the approval is accelerated, confirmatory clinical evidence continues to be required.
Datopotamab deruxtecan is an antibody-drug conjugate rather than another EGFR TKI. Important risks include interstitial lung disease/pneumonitis, eye problems, and stomatitis, so careful monitoring is required.
Clinical trials and resistance-directed treatment
Clinical trials can be especially important after osimertinib because several resistance mechanisms do not yet have an established approved treatment.
Studies are evaluating next-generation EGFR inhibitors, EGFR-MET combinations, antibody-drug conjugates, and other biomarker-directed strategies. A trial may be particularly relevant when molecular profiling reveals a specific resistance alteration.
How Should You Prepare for the Next Treatment Decision?
The most useful next step is usually to understand exactly what “progression” means in your case. Ask whether one site is growing or many, whether the brain has been reassessed, and whether a tissue biopsy or liquid biopsy could change the treatment choice.
Useful questions for an oncology appointment include:
Where exactly has the cancer progressed?
Is this oligoprogression or widespread progression?
Should I have a new tissue biopsy, liquid biopsy, or both?
Has the tumor developed MET amplification, EGFR C797S, histological transformation, or another resistance mechanism?
Could local treatment allow me to continue Tagrisso?
Have I previously received platinum and pemetrexed?
Is amivantamab plus chemotherapy appropriate and available for my situation?
If I have already received platinum chemotherapy, am I eligible for an antibody-drug conjugate or another treatment?
Are there clinical trials specifically for my resistance mechanism?
What treatment side effects and quality-of-life trade-offs should I expect?
Treatment sequence is increasingly important because today's first-line regimens are more varied. Some patients receive osimertinib alone, while others receive osimertinib with chemotherapy or another EGFR-directed first-line strategy.
Your previous treatment history therefore matters just as much as the fact that the cancer has progressed.
When Should New Symptoms Be Reported Urgently?
New or rapidly worsening symptoms during treatment should be reported promptly rather than waiting for the next routine scan. Progression is one possible explanation, but infection, blood clots, treatment toxicity, fluid around the lungs, and other treatable problems can produce similar symptoms.
Seek urgent or emergency medical assessment for severe or rapidly worsening breathing difficulty, coughing up significant amounts of blood, a first seizure, sudden weakness or numbness, new severe confusion, loss of consciousness, or other major neurological changes. Lung cancer that spreads to the brain can cause symptoms such as headache, weakness, balance problems, confusion, or seizures.
A new symptom does not prove that Tagrisso has stopped working. Imaging and clinical assessment are needed to establish the cause.
Conclusion
When Tagrisso stops working, the next step is not simply to choose another pill. Doctors first determine whether progression is limited or widespread and may use imaging, liquid biopsy, and tissue biopsy to identify how the cancer has changed. Depending on previous treatment and molecular findings, options can include local radiation, chemotherapy, amivantamab-based treatment, later-line antibody-drug conjugates, or clinical trials.
Do not stop Tagrisso or change treatment based on a scan report alone. An EGFR-focused thoracic oncology review can help match the progression pattern and resistance mechanism to the most appropriate available strategy.
Frequently Asked Questions
1. Does Tagrisso eventually stop working for everyone?
In advanced EGFR-mutated lung cancer, acquired resistance commonly develops over time, but the timing and mechanism vary widely. Some patients remain controlled considerably longer than others. Progression can also be limited to only a few sites rather than occurring throughout the body.
2. Can Tagrisso start working again after it stops?
Sometimes osimertinib may remain useful after limited progression, particularly when resistant sites can be treated locally. Rechallenge is also being studied in selected situations. This is not appropriate for everyone, so restarting or continuing Tagrisso should only occur under oncology supervision.
3. What is the most common next treatment after Tagrisso?
There is no single next treatment for everyone. Platinum-based chemotherapy remains important, while amivantamab plus carboplatin and pemetrexed is FDA-approved for certain EGFR exon 19 deletion or L858R cancers progressing after an EGFR TKI. Previous treatments and molecular findings affect the choice.
4. Should I have another biopsy when Tagrisso stops working?
Often it is worth discussing. Tissue and liquid biopsies can identify different resistance mechanisms, and tissue is particularly important if doctors suspect histological transformation. Whether biopsy is feasible depends on the location of the progressing cancer and whether the result could change treatment.
5. Can radiation help if only one cancer spot grows on Tagrisso?
Potentially. For oligoprogression, local radiation may control a resistant site while osimertinib continues controlling cancer elsewhere. Evidence supports considering this selectively, but prospective data remain limited, so the decision depends on the number, location, and safety of treating the progressing lesions.
Comments